Improving fascin inhibitors to block tumor cell migration and metastasis

Molecular Oncology - Tập 10 - Trang 966-980 - 2016
Shaoqin Han1,2, Jianyun Huang2, Bingqian Liu2, Bowen Xing2, Francois Bordeleau3, Cynthia A. Reinhart-King3, Wenxin Li1, J. Jillian Zhang2, Xin-Yun Huang2
1College of Life Sciences, Wuhan University, Wuhan, China
2Department of Physiology and Biophysics, Cornell University, Weill Medical College, New York, NY 10065, USA
3Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA

Tóm tắt

Tumor metastasis is the major cause of mortality of cancer patients, being responsible for ∼90% of all cancer deaths. One of the key steps during tumor metastasis is tumor cell migration which requires actin cytoskeletal reorganization. Among the critical actin cytoskeletal protrusion structures are antenna‐like filopodia. Fascin protein is the main actin‐bundling protein in filopodia. Here we report the development of fascin‐specific small‐molecules that inhibit the interaction between fascin and actin. These inhibitors block the in vitro actin‐binding and actin‐bundling activities of fascin, tumor cell migration and tumor metastasis in mouse models. Mechanistically, these inhibitors likely occupy one of the actin‐binding sites, reduce the binding of actin filaments, and thus lead to the inhibition of the bundling activity of fascin. At the cellular level, these inhibitors impair actin cytoskeletal reorganization. Our data indicate that target‐specific anti‐fascin agents will have great potential for treating metastatic tumors.


Tài liệu tham khảo

10.1016/j.ceb.2004.07.009 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L 10.1038/323712a0 10.1091/mbc.E09-05-0373 10.1016/0022-2836(78)90345-5 Cao D., 2005, Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary, Int. J. Gynecol. Pathol, 24, 67 10.1038/nature08978 10.1038/nmat1718 10.1002/1097-0169(200102)48:2<109::AID-CM1002>3.0.CO;2-G 10.1146/annurev.cellbio.21.122303.120306 Coopman P.J., 1998, Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity, Clin. Cancer Res, 4, 507 10.1158/1078-0432.CCR-08-1789 10.1038/361721a0 10.1053/j.seminoncol.2011.05.009 10.1016/j.cub.2014.05.023 10.1038/nrc1098 10.1053/j.seminoncol.2011.04.003 10.1054/bjoc.2000.1395 10.1242/jcs.02565 10.1002/path.2894 10.1159/000081327 10.1016/j.biocel.2005.05.004 10.1038/ncomms8465 10.1146/annurev.cellbio.21.020604.150721 10.1074/jbc.M111.251439 10.1083/jcb.201406102 10.1515/cclm-2014-1016 10.1053/j.gastro.2014.01.046 10.4161/cib.3.3.11556 10.1309/3PAM-P5WL-2LV0-R4EG 10.1038/nrm2406 10.1529/biophysj.104.056515 10.1083/jcb.200709134 10.1016/0092-8674(79)90154-5 10.1073/pnas.86.4.1254 10.1016/S0169-5002(03)00294-0 Pulaski B.A., 1998, Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines, Cancer Res, 58, 1486 10.1158/1078-0432.CCR-05-2281 10.1038/nrc3078 10.1245/s10434-013-3286-x 10.1038/nature12157 10.1016/j.ejcb.2014.08.002 10.1016/j.jmb.2010.04.043 10.1073/pnas.0500658102 10.1158/2159-8290.CD-11-0239 10.1002/jso.21867 10.1186/1741-7015-11-52 10.1016/j.lungcan.2013.08.017 10.1083/jcb.143.1.121 10.1083/jcb.200603013 10.1083/jcb.200208059 10.1038/nature14971 Wang W., 2002, Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling, Cancer Res, 62, 6278 10.1002/cm.20356 10.1016/S0021-9258(18)89183-9 10.1083/jcb.103.2.631 10.1074/jbc.M112.427971 10.1016/j.ccr.2008.12.019 10.1158/1078-0432.186.11.1 10.1016/j.urology.2006.03.032